Protara Therapeutics Inc (TARA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Protara Therapeutics Inc (TARA) has a cash flow conversion efficiency ratio of -0.118x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-21.34 Million) by net assets ($181.21 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See how many days can Protara Therapeutics Inc fund operations to measure how many days the company can operate on defensive assets alone.
Protara Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2012–2025)
This chart illustrates how Protara Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Protara Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Protara Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Bastas Baskent Cimento Sanayi ve Ticaret AS
IS:BASCM
|
0.160x |
|
Silicon Valley Acquisition Corp. Class A Ordinary Shares
NASDAQ:SVAQ
|
N/A |
|
Dogan Burda Dergi Yayincilik ve Pazarlama AS
IS:DOBUR
|
0.164x |
|
X3 Acquisition Corp. Ltd. Class A Ordinary Shares
NASDAQ:XCBE
|
-0.001x |
|
Jiangxi Changyun Co Ltd
SHG:600561
|
0.057x |
|
India Nippon Electricals Limited
NSE:INDNIPPON
|
0.001x |
|
Churchill Capital Corp X Class A Ordinary Shares
NASDAQ:CCCX
|
-0.003x |
|
Electromed Inc
NYSE MKT:ELMD
|
0.067x |
Annual Cash Flow Conversion Efficiency for Protara Therapeutics Inc (2012–2025)
The table below shows the annual cash flow conversion efficiency of Protara Therapeutics Inc from 2012 to 2025. For the full company profile with market capitalisation and key ratios, see Protara Therapeutics Inc market cap and net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $196.41 Million | $-56.37 Million | -0.287x | -33.94% |
| 2024-12-31 | $167.13 Million | $-35.81 Million | -0.214x | +61.03% |
| 2023-12-31 | $68.32 Million | $-37.56 Million | -0.550x | -112.10% |
| 2022-12-31 | $102.08 Million | $-26.46 Million | -0.259x | -21.63% |
| 2021-12-31 | $161.91 Million | $-34.50 Million | -0.213x | -81.38% |
| 2020-12-31 | $199.24 Million | $-23.41 Million | -0.117x | +95.20% |
| 2019-12-31 | $6.39 Million | $-15.65 Million | -2.448x | -115.38% |
| 2018-12-31 | $20.44 Million | $-23.23 Million | -1.136x | -76.63% |
| 2017-12-31 | $34.74 Million | $-22.35 Million | -0.643x | -4.42% |
| 2016-12-31 | $38.44 Million | $-23.69 Million | -0.616x | -122.42% |
| 2015-12-31 | $63.41 Million | $-17.57 Million | -0.277x | -128.68% |
| 2014-12-31 | $82.46 Million | $-9.99 Million | -0.121x | -107.43% |
| 2013-12-31 | $-4.11 Million | $-6.70 Million | 1.631x | +171.92% |
| 2012-12-31 | $3.63 Million | $-8.23 Million | -2.268x | -- |
About Protara Therapeutics Inc
Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations. It is also developing intravenous cholin… Read more